A personalized medical review ensures that the treatment is both safe and effective for your health needs
A 2026 study published in The Lancet suggests that tirzepatide, a dual GLP-1 and GIP receptor agonist already approved for treatment of diabetes and obesity, could be an effective tool for fighting alcohol use disorder (AUD)
The mixed results are confusing, but they also serve as a reminder that the most effective GLP-1 is the one you will remember to take, can administer properly, and can tolerate its side effects
It supports the glutathione-dependent enzymes and assists glutathione S-transferases, both important actions for detoxification
The Golden Rule: Injection Timing INJECT ONLY DURING NON-FASTING HOURS within your eating window between sunset (Iftar) and dawn (Suhoor)
Welldocs digital health platform understands this synergy